Analysis of the Effects and Incidence of Adverse Reactions of Hormone Replacement Therapy for Perimenopausal Syndrome

Abstract

Objective: To introduce hormone replacement therapy for patients with perimenopausal syndrome and observe its clinical application effect. Methods: Patients with perimenopausal syndrome were the subjects of this study, with a total of 110 participants clinically admitted from January 2022 to December 2023. Upon enrollment, patients were divided into groups based on differences in treatment modes. The observation group (n = 55) received routine health care combined with hormone replacement therapy, while the control group (n = 55) received only routine health care treatment. Evaluation criteria included psychological state, symptom scores, improvement in hormone levels, and the incidence of adverse reactions. The clinical effects of different treatment options were compared. Results: Post-treatment, scores of the Self-Rating Anxiety Scale (SAS) and the Self-Rating Depression Scale (SDS) in the observation group were significantly lower than those in the control group (P < 0.05). Additionally, the female menopausal syndrome self-diagnosis assessment scale (Kupperman) score was 12.31 ± 1.25 points in the observation group compared to 15.22 ± 1.84 points in the control group (t = 9.7018, P < 0.05). Furthermore, levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were lower in the observation group than in the control group, while estradiol (E2) and progesterone levels were higher in the observation group than in the control group (P < 0.05). There was no statistically significant difference in the total incidence of adverse reactions between the observation and control groups (P > 0.05). Conclusion: The application of hormone replacement therapy in Chinese medicine can improve patients’ mental state, alleviate clinical symptoms, and restore hormone levels. This treatment modality is deemed safe with minimal adverse reactions, thus offering positive value.